The clinical trials industry is becoming, on the one hand, increasingly competitive with new players and new domains of investigation. On the other hand, legal and quality requirements are becoming more restrictive.
All of these factors contribute to an increased risk of financial failure in the development of new drugs. Consequently, in the future, the decisional speed and the speed of realization of the project will be the principal criteria for the selection of the reliable partners by the pharmaceutical companies.
|
